Logo of Racura Oncology (ASX:RAC)Latest Racura Oncology (ASX:RAC) News

Page 5
Page 5 of 5

Race Oncology Safely Advances RC220-Doxorubicin Combo in Solid Tumour Trial

Race Oncology has successfully dosed the first patient with its RC220 and doxorubicin combination in a Phase 1 trial for advanced solid tumours, reporting no dose-limiting side effects. This milestone marks a key step in evaluating the safety and potential cardioprotective benefits of the novel therapy.
Ada Torres
19 June 2025

Race Oncology Accelerates RC220 Trial with Second Australian Site Activation

Race Oncology has opened a second Australian clinical site for its Phase 1 trial of RC220 combined with doxorubicin in advanced solid tumours, aiming to speed patient enrolment and gather critical safety and efficacy data.
Ada Torres
22 Apr 2025

Race Oncology Nears Phase 1 Trial Start with $18.8M Cash Boost

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.
Victor Sage
31 Jan 2025